→ Let’s start Protocols off this morning with some news about people on the move.
In personal news, after 9 great years w SR One I’m thrilled to announce I’m joining @Abingworthbio as partner & head of the boston office. I’m honored to continue to work w so many talented entrepreneurs, coinvestors, colleagues & friends in building world class biotech companies
— Brian Gallagher, Jr. (@bmgallagherjr) September 20, 2018
→ Portola $PTLA, meanwhile, has turned to an experienced commercial exec for its new CEO. Scott Garland is joining the company from Relypsa, where he was president. Earlier Garland had been an EVP at Exelixis and has a resume that includes a stint at Genentech.
→ Tapping a growing need for medical aesthetics professionals in what is now the second largest healthcare market in the world, Allergan $AGN is building its first training center in Chengdu, China, where it expects to train 3,000 practitioners per year. The Medical Aesthetics Innovation Center housing the training facility will also feature an education and experience hub for consumers to have a taste of the Botox maker’s latest products. The center, which costs a total of $14.7 million, is scheduled to open to the public in early 2019.
→ FibroGen’s $FGEN partners at Astellas say they got another positive batch of Phase III data on roxadustat, their candidate to treat anemia in chronic kidney disease patients. Their ALPS study is the first of three late-stage trials that are being concluded primarily in Europe — all part of an ambitious global development program aimed at disrupting the market in this field.
→ China/US hybrid BeiGene posted a snapshot of early data from a Phase I/II study of its PD-1 tislelizumab in patients with microsatellite instability-high or mismatch repair-deficient solid tumors.
→ Corbus Pharmaceuticals has picked up a big batch of drugs targeting the endocannabinoid system in a new licensing pact with Jenrin Discovery. The deal kicks off with a light $250,000 upfront, according to the SEC filing, with up to $18.4 million in milestones on anything that can make the distance.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,900+ biopharma pros who read Endpoints News by email every day.Free Subscription